A Nature Biotechnology analysis of 42 rentosertib-treated IPF trial participants found younger predicted biological-age profiles across six proteomic clocks, but researchers caution that the finding does not prove human aging was reversed.
Co-Diagnostics has completed the first international deployment of its Vector Smart mosquito surveillance platform, supplying an overseas U.S. Air Force base with local molecular testing and mosquito-abatement materials.
Sonorous Neurovascular has expanded its B-SILENT study into Toronto, testing the investigational BosSTENT in patients with severe pulse-synchronous tinnitus caused by cerebral venous sinus stenosis.
Cipla’s Invagen has licensed U.S. rights to Qilu’s investigational pembrolizumab biosimilar QL2107, setting up a future challenge to Merck’s blockbuster Keytruda franchise.
An NYU Langone study of more than 3.5 million children found rapidly increasing off-label GLP-1 prescribing below age 12, concentrated among children with severe obesity and related disease.
Menarini has licensed European rights to Gan & Lee’s twice-monthly GLP-1 bofanglutide after a 640-patient Phase 3 study produced up to 18.54% mean weight loss at 52 weeks.
Evinova and Lothar Medical will integrate a three-in-one pulmonary assessment device with a clinical-trial platform already used at more than 4,000 sites in 54 countries.
Texas Cardiac Arrhythmia Institute has performed the first U.S. procedure in Boston Scientific’s 571-patient FARAFLEX pivotal program evaluating integrated mapping and pulsed field ablation for paroxysmal and persistent AF.
Interim MASTRR Registry results across 10 U.S. centers found no adverse events definitely related to Aroa’s Myriad products and low infection rates despite a highly complex wound population.
Sky Labs reports new ESC 2026 data supporting ring-based 24-hour blood pressure monitoring in atrial fibrillation and severe heart failure, as CART BP pro expands beyond conventional cuff monitoring.